PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
(the “Company” or “PAVmed”), a highly differentiated,
multi-product, commercial-stage medical technology company, today
announced the appointment of prominent UK-based global industry
executive, Debbie White, to its Board of Directors. Ms. White will
serve on the Company’s Audit and Compensation Committees.
“I am delighted to welcome Debbie White to
PAVmed’s Board of Directors,” said Lishan Aklog M.D., PAVmed’s
Chairman and Chief Executive Officer. “Debbie has broad business
leadership experience, including as a chief executive, financial
executive, public company director and strategic consultant, in
multiple sectors in Europe and the United States, including the
healthcare services, molecular genetics and biopharmaceutical
industries. She will provide valuable guidance on strategy,
operations, finance and international commercialization as PAVmed
transitions to a growth-stage commercial company.”
“I am very excited to join this rapidly-growing
innovative company with groundbreaking medical technologies, which
have the potential to greatly improve patient care and save lives
across the world,” said Ms. White. “I look forward to working with
Dr. Aklog, the rest of PAVmed’s strong management team and my
respected board colleagues to hone and execute the company’s
long-term growth strategy.”
Ms. White currently serves on the board of
directors of Howden Joinery Group PLC (LSE: HWDN), a
UK-headquartered FTSE250 multinational building trade supplier with
10,000 employees and over $2 billion in revenue and as a trustee of
Wellbeing of Women, a UK charity which invests in medical research
and development of specialist clinicians in women’s health. Ms.
White recently served as a strategic consultant to Oxford Nanopore
Technologies Ltd., a UK biotechnology company that develops and
commercializes DNA/RNA sequencing technologies, and its emerging
Oxford Nanopore Diagnostics business unit.
Early in the COVID-19 pandemic, Ms. White worked
with the UK government to help establish COVID-19 testing
facilities across the nation.
Ms. White previously served as Group CEO of
Interserve Group (LSE: IRV), a UK-headquartered multinational group
of support services and construction companies with 75,000
employees and over $4 billion in revenue, during a challenging
period which required her to implement complex strategic financing
and operational programs prior to its restructuring and sale to its
creditors.
Prior to Interserve, Ms. White spent 13 years in
senior executive roles at Sodexo SA (EuroNext: SW), a
Paris-headquartered multinational diversified services company with
440,000 employees and over $20 billion in revenue, including as
Chief Executive Officer of Sodexo UK & Ireland, Chief Financial
Officer of Sodexo North America, an $8 billion subsidiary, and
finally as Executive Board member and Global Chief Executive
Officer of Healthcare and Government, two global businesses with a
combined 100,000 employees and over $7 billion in revenue. While at
Sodexo, she served on its global body that promoted the development
of women across the company and was inducted into the industry’s
Women 1st Top 100 Club, which highlights the female role models and
leaders who have achieved success at the highest levels.
Prior to Sodexo, Ms. White served for 3 years as
a Director at PWC Consulting, advising a range of industries,
including pharmaceuticals, on integration, financial performance
improvement and post-merger integration, and for 13 years in
various financial and strategic roles at AstraZeneca (LSE: AZN), a
UK-headquartered multinational pharmaceutical and biotechnology
company. She began her career as a senior tax advisor at Arthur
Andersen & Co. Ms. White received her master’s degree in
Economics from Cambridge University, Cambridge UK.
About
PAVmedPAVmed Inc. is a highly differentiated,
multi-product, commercial-stage medical technology company with a
diversified product pipeline addressing unmet clinical needs
encompassing a broad spectrum of clinical areas with attractive
regulatory pathways and market opportunities. Its major subsidiary,
Lucid Diagnostics Inc., markets the first and only commercial tools
for widespread early detection of esophageal precancer and cancer –
the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell
Collection Device. Its GI Health division also includes the
complementary EsoCure™ Esophageal Ablation Device with Caldus™
Technology. Its Minimally Invasive Interventions markets its CarpX®
Minimally Invasive Device for Carpal Tunnel Syndrome. Other
divisions include Infusion Therapy (PortIO™ Implantable Intraosseus
Vascular Access Device and NextFlo™ Intravenous Infusion Set), and
Emerging Innovations (non-invasive laser-based glucose monitoring,
pediatric ear tubes, and mechanical circulatory support). For more
information, please visit www.pavmed.com, follow us on
Twitter, connect with us on LinkedIn, and watch our videos on
YouTube. For more information on our majority owned subsidiary,
Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid
on Twitter, and connect with Lucid on LinkedIn. For detailed
information on EsoGuard, please visit www.EsoGuard.com and follow
us on Twitter, Facebook and Instagram.
Forward-Looking StatementsThis
press release includes forward-looking statements that involve
risks and uncertainties. Forward-looking statements are statements
that are not historical facts. Such forward-looking statements,
based upon the current beliefs and expectations of PAVmed’s
management, are subject to risks and uncertainties, which could
cause actual results to differ from the forward-looking statements.
Risks and uncertainties that may cause such differences include,
among other things, volatility in the price of PAVmed’s common
stock, Series W Warrants and Series Z Warrants; general economic
and market conditions; the uncertainties inherent in research and
development, including the cost and time required advance PAVmed’s
products to regulatory submission; whether regulatory authorities
will be satisfied with the design of and results from PAVmed’s
preclinical studies; whether and when PAVmed’s products are cleared
by regulatory authorities; market acceptance of PAVmed’s products
once cleared and commercialized; our ability to raise additional
funding and other competitive developments. PAVmed has not yet
received clearance from the FDA or other regulatory body to market
many of its products. The Company has been monitoring the COVID-19
pandemic and its impact on our business. The Company expects the
significance of the COVID-19 pandemic, including the extent of its
effect on the Company’s financial and operational results, to be
dictated by, among other things, the success of efforts to contain
it and the impact of actions taken in response. New risks and
uncertainties may arise from time to time and are difficult to
predict. All of these factors are difficult or impossible to
predict accurately and many of them are beyond PAVmed’s control.
For a further list and description of these and other important
risks and uncertainties that may affect PAVmed’s future operations,
see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, as the same may be updated in Part II, Item 1A, “Risk
Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after
its most recent Annual Report. PAVmed disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
Contacts:InvestorsMike HavrillaDirector of
Investor Relations(814) 241-4138JMH@PAVmed.com
MediaShaun O’NeilChief Commercial Officer(518)
812-3087SMO@PAVmed.com
Jim Heins / Katie GallagherLaVoieHealthScience(646) 491-7042 /
(617) 792-3937PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Jul 2023 to Jul 2024